ArticleProceedings of the National Academy of Sciences of the United States of America2022
Inhibition of the angiotensin II type 2 receptor AT
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Radiolabeled Angiopep-2 Peptide Vector as a Preclinical Platform for Blood-Brain Barrier Targeting: Synthesis, Radiolabeling, and Preliminary In Vivo Biodistribution in Mice.Journal of peptide science : an official publication of the European Peptide Society · 2026Article
- Post-traumatic stress disorder and cardiometabolic dysfunction: Molecular mechanisms and therapeutic targets.iScience · 2026Review
- Advances in Understanding Renin-Angiotensin System-Mediated Anti-Tumor Activity of Natural Polyphenols.Biomolecules · 2025Review
- Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025Review
- Renin-angiotensin system as an emerging target to modulate adult neurogenesis in health and disease.Stem cell research & therapy · 2025Review
- Gating Mechanism for Biased Agonism at Angiotensin II Type 1 Receptors.Molecules (Basel, Switzerland) · 2025Article
- Neuropeptide Signaling in Glioblastoma: A Comprehensive Review of the Current State and Future Direction.Neuromolecular medicine · 2025Review
- Targeting stromal cells in tumor microenvironment as a novel treatment strategy for glioma.Cancer cell international · 2025Review
- Glioma and Peptidergic Systems: Oncogenic and Anticancer Peptides.International journal of molecular sciences · 2024Review
- Article
- Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation.Current opinion in pharmacology · 2023Review
- Comparing tumor microRNA profiles of patients with long‑ and short‑term‑surviving glioblastoma.Molecular medicine reports · 2023Article
- The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 9 institutions in 6 countries.
Richard PerrymanJohn Fulcher Molecular Neuro-Oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom.
Alexander RenziehausenJohn Fulcher Molecular Neuro-Oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom.ORCID 0000-0002-6304-0291
Hamidreza ShayeDepartment of Chemistry, University of Southern California, Los Angeles, CA 90089.ORCID 0000-0002-8670-1259
Androniki D KostagianniDepartment of Chemistry, University of Ioannina, Ioannina, Greece.
Antonis D TsiailanisDepartment of Chemistry, University of Ioannina, Ioannina, Greece.
Thomas ThorneDepartment of Computer Science, University of Surrey, Surrey, United Kingdom.ORCID 0000-0002-7396-5116
Maria V ChatziathanasiadouJohn Fulcher Molecular Neuro-Oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom.ORCID 0000-0002-9136-981X
Gregory B SivolapenkoLaboratory of Pharmacokinetics, Department of Pharmacy, University of Patras, Patras, Greece.ORCID 0000-0003-2388-362X
Mohamed Ahmed El MubarakLaboratory of Pharmacokinetics, Department of Pharmacy, University of Patras, Patras, Greece.ORCID 0000-0002-2575-3565
Gye Won HanBridge Institute, University of Southern California, Los Angeles, CA 90089.ORCID 0000-0003-4107-835X
Barbara ZarzyckaBridge Institute, University of Southern California, Los Angeles, CA 90089.
Vsevolod KatritchBridge Institute, University of Southern California, Los Angeles, CA 90089.ORCID 0000-0003-3883-4505
Guillaume LebonInstitut de Génomique Fonctionnelle, University of Montpellier, CNRS, INSERM, Montpellier, France.ORCID 0000-0003-1162-5148
Cristiana Lo NigroDepartment of Oncology, Ospedale San Croce e Carle, Cuneo, Italy.ORCID 0000-0002-3615-2431
Laura LattanzioDepartment of Oncology, Ospedale San Croce e Carle, Cuneo, Italy.
Sophie V MorseJohn Fulcher Molecular Neuro-Oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom.ORCID 0000-0001-5184-0200
James J ChoiDepartment of Bioengineering, Imperial College London, London, United Kingdom.ORCID 0000-0002-4850-8204
Kevin O'NeillJohn Fulcher Molecular Neuro-Oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom.
Zoi KanakiCentre for Basic Research, Biomedical Research Foundation of the Academy of Athens, Greece.ORCID 0000-0003-4661-5214
Apostolos KlinakisCentre for Basic Research, Biomedical Research Foundation of the Academy of Athens, Greece.ORCID 0000-0002-3923-861X
Tim CrookJohn Fulcher Molecular Neuro-Oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom.
Vadim CherezovDepartment of Chemistry, University of Southern California, Los Angeles, CA 90089.ORCID 0000-0002-5265-3914
Andreas G TzakosDepartment of Chemistry, University of Ioannina, Ioannina, Greece.ORCID 0000-0001-6391-0288
Nelofer SyedJohn Fulcher Molecular Neuro-Oncology Laboratory, Department Brain Sciences, Imperial College, London, United Kingdom.ORCID 0000-0003-1104-5805
Imperial College London · GBUniversity of Southern California · USUniversity of Ioannina · GRAcademy of Athens · GRAzienda Sanitaria Ospedaliera S.Croce e Carle Cuneo · ITUniversity of Patras · GRCentre National de la Recherche Scientifique · FRCharing Cross Hospital · GBUniversity of Surrey · GB
Funding
Structural Biology Of G Protein-Coupled ReceptorsR35GM127086 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Vadim Cherezov · 2018 to 2026
$3.6MHigh-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0MNon-addictive Angiotensin AT2 inhibitors for neuropathic pain reliefUH3NS116929 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEREZOV, VADIM, KATRITCH, VSEVOLOD · 2021 to 2023
$1.9MNon-addictive Angiotensin AT2 inhibitors for neuropathic pain reliefUG3NS116929 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEREZOV, VADIM, KATRITCH, VSEVOLOD · 2020 to 2020
$484kNational Institute of Health R35GM127086National Institute of Health UG3NS116929NCI NIH HHS ACB-12002NIGMS NIH HHS AGM-12006NIGMS NIH HHS R35 GM127086NIH HHS S10 OD012289NINDS NIH HHS UG3 NS116929NINDS NIH HHS UH3 NS116929ODCDC CDC HHS S10 OD012289
Abstract
Glioblastoma (GBM) is an aggressive malignant primary brain tumor with limited therapeutic options. We show that the angiotensin II (AngII) type 2 receptor (AT
Indexed as
Angiotensin II Type 2 Receptor BlockersBenzhydryl CompoundsBrain NeoplasmsDrug RepositioningGlioblastomaIsoquinolinesReceptor, Angiotensin, Type 2AnalgesicsAngiotensin IIApoptosisHumansProtein Conformation, alpha-HelicalTumor BurdenAnalgesicsAngiotensin IIAngiotensin II Type 2 Receptor BlockersBenzhydryl CompoundsEMA400IsoquinolinesReceptor, Angiotensin, Type 2angiotensin IIglioblastomarenin angiotensin system
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.